We are live on ! Find out more
SC

Sophrosyne Capital Portfolio holdings

AUM $11.5M
1-Year Est. Return 17.82%
This Fund
S&P 500
This Quarter Est. Return
+16.88%
1 Year Est. Return
+17.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$64.8M
AUM Growth
-$19.9M
Cap. Flow
-$24.5M
Cap. Flow %
-37.79%
Top 10 Hldgs %
64.49%
Holding
63
New
5
Increased
6
Reduced
22
Closed
23

Top Buys

Rank Stock Value
1
CYNO
Cynosure, Inc. Class A
CYNO
+$576K
2
IPHI
INPHI CORPORATION
IPHI
+$541K
3
RTK
Rentech, Inc.
RTK
+$444K
4
CEMI
Chembio diagnostics, Inc.
CEMI
+$428K
5
REFR icon
Research Frontiers
REFR
+$413K

Top Sells

Rank Stock Value
1
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$5M
2
MSTR icon
Strategy Inc
MSTR
+$2.79M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$2.47M
4
FLNA
Filana Therapeutics
FLNA
+$2.27M
5
DRRX
DURECT Corp
DRRX
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 50%
2 Technology 18.71%
3 Utilities 9.18%
4 Communication Services 7.12%
5 Financials 5.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAT
1
DELISTED
BioTelemetry, Inc.
BEAT
$10.6M 16.27%
1,052,142
-74,832
-7% -$642K
ZLTQ
2
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$5.38M 8.29%
192,597
-191,821
-50% -$5M
IRMD icon
3
iRadimed
IRMD
$1.11B
$4.5M 6.95%
349,300
-29,471
-8% -$254K
MSTR icon
4
Strategy Inc
MSTR
$54.6B
$4.4M 6.79%
271,120
-176,380
-39% -$2.79M
BFYT
5
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$3.43M 5.29%
479,120
-40,750
-8% -$344K
PCYO icon
6
Pure Cycle
PCYO
$275M
$3.25M 5.01%
811,920
-4,228
-0.5% -$22.6K
CDZI icon
7
Cadiz
CDZI
$334M
$2.71M 4.17%
241,479
-16,800
-7% -$175K
CSII
8
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.56M 3.95%
85,100
-6,741
-7% -$193K
BDSI
9
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.54M 3.92%
211,619
+19,443
+10% +$295K
MEET
10
DELISTED
The Meet Group, Inc. Common Stock
MEET
$2.49M 3.84%
1,629,327
-133,500
-8% -$232K
CYNO
11
DELISTED
Cynosure, Inc. Class A
CYNO
$2.46M 3.79%
89,700
+22,700
+34% +$576K
RTK
12
DELISTED
Rentech, Inc.
RTK
$2.15M 3.32%
170,880
+31,360
+22% +$444K
AXGN icon
13
Axogen
AXGN
$2.78B
$1.76M 2.71%
489,729
-60,878
-11% -$178K
PKT
14
DELISTED
PROCERA NETWORKS INC NEW COM STK (DE)
PKT
$1.67M 2.57%
231,806
-9,100
-4% -$65K
SILC icon
15
Silicom
SILC
$274M
$1.59M 2.46%
45,300
-2,800
-6% -$93.6K
SHOR
16
DELISTED
ShoreTel, Inc.
SHOR
$1.54M 2.38%
209,828
-14,732
-7% -$109K
ENT
17
DELISTED
Global Eagle Entertainment Inc.
ENT
$1.39M 2.15%
4,104
-728
-15% -$225K
AVAV icon
18
AeroVironment
AVAV
$7.74B
$1.35M 2.09%
49,600
+11,500
+30% +$329K
IPHI
19
DELISTED
INPHI CORPORATION
IPHI
$1.26M 1.94%
68,300
+37,000
+118% +$541K
ALT icon
20
Altimmune
ALT
$630M
$903K 1.39%
1,667
– –
UI icon
21
Ubiquiti
UI
$35.9B
$839K 1.29%
28,400
-3,313
-10% -$106K
TPST icon
22
Tempest Therapeutics
TPST
$17.9M
$767K 1.18%
6
-13
-68% -$952K
P
23
DELISTED
Pandora Media Inc
P
$734K 1.13%
41,100
-1,200
-3% -$23.7K
ENVI
24
DELISTED
ENVIVIO INC COM STK (DE)
ENVI
$705K 1.09%
525,574
+90,252
+21% +$137K
CKSW
25
DELISTED
CLICKSOFTWARE TECH LTD
CKSW
$684K 1.05%
95,400
-31,300
-25% -$231K
1
2 3

Similar funds

SFM
Socratic Fund Management Short Hills, New Jersey $12M AUM 39.3% 1-Year Est. Return
IACGFA
IDG-Accel China Growth Fund Associates Central, Hong Kong $13.2M AUM 31.6% 1-Year Est. Return
LS
Lupo Securities Chicago, Illinois $13.3M AUM 1.59% 1-Year Est. Return
NGPI
N.G. Partners II Palo Alto, California $9.65M AUM 70.44% 1-Year Est. Return
AP
AGTC Partners Cambridge, Massachusetts $13.6M AUM 15.62% 1-Year Est. Return
GRP
Geologic Resource Partners Boston, Massachusetts $9.22M AUM 48.14% 1-Year Est. Return
NVPV
Norwest Venture Partners VIII Palo Alto, California $9.22M AUM
AC
Amiya Capital London, United Kingdom $14.3M AUM 4.61% 1-Year Est. Return

Sophrosyne Capital's Q4 2014 Portfolio in Review

As of Q4 2014, Sophrosyne Capital held 63 positions worth $64.8M, down 23% from $84.7M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Sophrosyne Capital withdrew a net $24.5M in Q4 2014, closing 23 positions and reducing 22 holdings. Its most notable exit was Arcturus Therapeutics, an estimated $2.47M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 44% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sophrosyne Capital opened a new position in Chembio diagnostics, Inc. worth $407K.

  • Sophrosyne Capital's largest Q4 2014 buy was Chembio diagnostics, Inc.: 103,400 shares worth $407K.
  • Sophrosyne Capital added most to Cynosure, Inc. Class A in Q4 2014, an estimated $576K increase.
  • Sophrosyne Capital's biggest Q4 2014 reduction was ZELTIQ Aesthetics, Inc., cutting an estimated $5M.
  • Sophrosyne Capital fully exited Arcturus Therapeutics in Q4 2014, selling an estimated $2.47M.
  • Sophrosyne Capital's ten largest holdings make up 64% of its $64.8M portfolio in Q4 2014.
  • Sophrosyne Capital opened 5 new positions and closed 23 in Q4 2014.
  • Sophrosyne Capital's portfolio value fell 23% quarter-over-quarter to $64.8M.

Based on Sophrosyne Capital's 13F filing for Q4 2014, filed 26 Jan 2015.